Triple negative breast cancer (TNBC) represents approximately 10–20% of breast cancers and is defined by a lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) receptor1. This evidence concerns the gene ERBB2 and breast carcinoma.